SOS2

Son of sevenless homolog 2 · Q07890 · SOS2 on Sugi Atlas →

2,904 patent compounds predicted against SOS2, 2,092 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Tacrine (SCHEMBL2828)	1.00	1/20
SCHEMBL596040	1.00	1/20
SCHEMBL906658	1.00	1/20
Tacrine (SCHEMBL3270)	0.97	1/20
Tacrine (SCHEMBL490750)	0.97	1/20
Tacrine (SCHEMBL1044163)	0.97	1/20
Tacrine (SCHEMBL2330283)	0.97	1/20
Tacrine (SCHEMBL2330285)	0.97	1/20
SCHEMBL5042118	0.97	1/20
SCHEMBL6401338	0.96	1/20
SCHEMBL6431724	0.96	1/20
Tacrine (SCHEMBL1650622)	0.93	1/20
Tacrine (SCHEMBL2236694)	0.93	1/20
Tacrine (SCHEMBL5580054)	0.93	1/20
SCHEMBL5047992	0.93	1/20
Tacrine (SCHEMBL4850100)	0.88	1/20
Tacrine (SCHEMBL5795221)	0.82	1/20
Hydrochloric Acid (SCHEMBL1190602)	0.79	1/20
SCHEMBL6012735	0.76	1/20
SCHEMBL4306126	0.73	1/20

Clinical trials — most relevant to SOS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients	PHASE4	WITHDRAWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Proteome-based Personalized Immunotherapy of Glioblastoma	PHASE2/PHASE3	UNKNOWN
Proteome-based Immunotherapy of Lung Cancer Brain Metastases	PHASE2/PHASE3	UNKNOWN
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	PHASE2	COMPLETED
A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement	PHASE2	UNKNOWN
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)	PHASE1	COMPLETED
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma	PHASE1	COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)	PHASE1	COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2	PHASE1	COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma	EARLY_PHASE1	RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
is the Sclerostin Marker of Chronic Periodontitis	nan	COMPLETED
Serum Sclerostin Levels, Cardiovascular Parameters and Carpal Tunnel Syndrome in Maintenance Hemodialysis Patients	nan	UNKNOWN
Hematological Anomalies in Children With Rasopathy	nan	RECRUITING
Natural History and Genetic Studies of Usher Syndrome	nan	COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
SS-HH-OCT as a Novel Diagnostic Modality for Early-Onset Retinal Dystrophies (EORDs)	nan	RECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases	nan	NOT_YET_RECRUITING
Genetic Identification (ID) of Segmental Dysplastic Nevi	nan	WITHDRAWN
Williams Syndrome (WS) and Supravalvar Aortic Stenosis (SVAS) DNA and Tissue Bank	nan	COMPLETED
Retrospective Natural History Study of RASopathy-associated Cardiomyopathy (RAS-CM)	nan	RECRUITING
Epidemiological and Genetic Studies of Body Mass Index	nan	COMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a SOS2 binder may also engage these)

Protein	Name	Similarity
Q62245	—	1.000	Q62245 →
Q02384	—	1.000	Q02384 →
SOS1	Son of sevenless homolog 1	1.000	landscape →
RAPGEF4	Rap guanine nucleotide exchange factor 4	0.976	landscape →
Q9R0C8	—	0.972	Q9R0C8 →
Q9H8V3	—	0.972	Q9H8V3 →
Q07139	—	0.971	Q07139 →
Q8K3G9	—	0.971	Q8K3G9 →
Q9Z1C7	—	0.971	Q9Z1C7 →
VAV1	Proto-oncogene vav	0.970	landscape →
Q8AVG0	—	0.970	Q8AVG0 →
Q9H3E2	—	0.970	Q9H3E2 →
Q9EQZ6	—	0.969	Q9EQZ6 →
P29994	—	0.969	P29994 →
P54100	—	0.969	P54100 →
A6NI28	—	0.968	A6NI28 →
A7MBL8	—	0.968	A7MBL8 →
Q3LAC4	—	0.968	Q3LAC4 →
Q8K3H0	—	0.967	Q8K3H0 →
Q9TU34	—	0.967	Q9TU34 →
Q8BWW9	—	0.966	Q8BWW9 →
Q9D4H1	—	0.966	Q9D4H1 →
Q9UKW4	—	0.966	Q9UKW4 →
Q7Z3V4	—	0.966	Q7Z3V4 →
B5DFQ4	—	0.966	B5DFQ4 →
B4F779	—	0.966	B4F779 →
Q8NEU8	—	0.966	Q8NEU8 →
P97878	—	0.965	P97878 →
Q08CZ0	—	0.965	Q08CZ0 →
Q5F361	—	0.965	Q5F361 →